[
  {
    "nct_id": "NCT04756765",
    "title": "Pembrolizumab Plus Chemotherapy in HER2-Negative Breast Cancer",
    "brief_summary": "A study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.",
    "conditions": [
      "Breast Cancer"
    ],
    "phase": "Phase 3",
    "status": "Recruiting",
    "eligibility": {
      "min_age": 18,
      "max_age": 75,
      "gender": "All",
      "inclusion_criteria": [
        "Confirmed diagnosis of Breast Cancer",
        "Stage II",
        "Adequate organ function"
      ],
      "exclusion_criteria": [
        "Prior systemic therapy for metastatic disease",
        "Active CNS metastases"
      ],
      "required_biomarkers": [
        "ER+",
        "HER2+"
      ],
      "excluded_biomarkers": []
    },
    "locations": [
      {
        "city": "Boston",
        "state": "MA",
        "country": "USA"
      },
      {
        "city": "New York",
        "state": "NY",
        "country": "USA"
      }
    ],
    "sponsor": "National Cancer Institute",
    "enrollment": 200,
    "interventions": [
      "Pembrolizumab"
    ]
  },
  {
    "nct_id": "NCT05633979",
    "title": "Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer",
    "brief_summary": "An open-label study of trastuzumab deruxtecan in participants with HER2-positive metastatic breast cancer.",
    "conditions": [
      "Breast Cancer"
    ],
    "phase": "Phase 2",
    "status": "Recruiting",
    "eligibility": {
      "min_age": 18,
      "max_age": 75,
      "gender": "All",
      "inclusion_criteria": [
        "Confirmed diagnosis of Breast Cancer",
        "Stage II",
        "Adequate organ function"
      ],
      "exclusion_criteria": [
        "Prior systemic therapy for metastatic disease",
        "Active CNS metastases"
      ],
      "required_biomarkers": [
        "ER+",
        "HER2+"
      ],
      "excluded_biomarkers": []
    },
    "locations": [
      {
        "city": "Boston",
        "state": "MA",
        "country": "USA"
      },
      {
        "city": "New York",
        "state": "NY",
        "country": "USA"
      }
    ],
    "sponsor": "National Cancer Institute",
    "enrollment": 200,
    "interventions": [
      "Trastuzumab"
    ]
  },
  {
    "nct_id": "NCT04873362",
    "title": "CDK4/6 Inhibitor With Endocrine Therapy",
    "brief_summary": "A study evaluating the efficacy and safety of ribociclib plus endocrine therapy in HR+/HER2- advanced breast cancer.",
    "conditions": [
      "Breast Cancer"
    ],
    "phase": "Phase 3",
    "status": "Recruiting",
    "eligibility": {
      "min_age": 18,
      "max_age": 75,
      "gender": "All",
      "inclusion_criteria": [
        "Confirmed diagnosis of Breast Cancer",
        "Stage II",
        "Adequate organ function"
      ],
      "exclusion_criteria": [
        "Prior systemic therapy for metastatic disease",
        "Active CNS metastases"
      ],
      "required_biomarkers": [
        "ER+",
        "HER2+"
      ],
      "excluded_biomarkers": []
    },
    "locations": [
      {
        "city": "Boston",
        "state": "MA",
        "country": "USA"
      },
      {
        "city": "New York",
        "state": "NY",
        "country": "USA"
      }
    ],
    "sponsor": "National Cancer Institute",
    "enrollment": 200,
    "interventions": [
      "CDK4/6"
    ]
  }
]